Literature DB >> 15155635

Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies.

Christian Maaser1, Michael P Housley, Mitsutoshi Iimura, Jennifer R Smith, Bruce A Vallance, B Brett Finlay, John R Schreiber, Nissi M Varki, Martin F Kagnoff, Lars Eckmann.   

Abstract

Citrobacter rodentium, a murine model pathogen for human enteropathogenic Escherichia coli, predominantly colonizes the lumen and mucosal surface of the colon and cecum and causes crypt hyperplasia and mucosal inflammation. Mice infected with C. rodentium develop a secretory immunoglobulin A (IgA) response, but the role of B cells or secretory antibodies in host defense is unknown. To address this question, we conducted oral C. rodentium infections in mice lacking B cells, IgA, secreted IgM, polymeric Ig receptor (pIgR), or J chain. Normal mice showed peak bacterial numbers in colon and feces at 1 week and bacterial eradication after 3 to 4 weeks. B-cell-deficient mice were equally susceptible initially but could not control infection subsequently. Tissue responses showed marked differences, as infection of normal mice was accompanied by transient crypt hyperplasia and mucosal inflammation in the colon and cecum at 2 but not 6 weeks, whereas B-cell-deficient mice had few mucosal changes at 2 weeks but severe epithelial hyperplasia with ulcerations and mucosal inflammation at 6 weeks. The functions of B cells were not mediated by secretory antibodies, since mice lacking IgA or secreted IgM or proteins required for their transport into the lumen, pIgR or J chain, cleared C. rodentium normally. Nonetheless, systemic administration of immune sera reduced bacterial numbers significantly in normal and pIgR-deficient mice, and depletion of IgG abrogated this effect. These results indicate that host defense against C. rodentium depends on B cells and IgG antibodies but does not require production or transepithelial transport of IgA or secreted IgM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155635      PMCID: PMC415672          DOI: 10.1128/IAI.72.6.3315-3324.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1.

Authors:  John McLay; Ethan Leonard; Sheryl Petersen; David Shapiro; Neil S Greenspan; John R Schreiber
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

2.  Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

Authors:  A Rivera; C C Chen; N Ron; J P Dougherty; Y Ron
Journal:  Int Immunol       Date:  2001-12       Impact factor: 4.823

3.  Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma.

Authors:  Cameron P Simmons; Nathalie S Goncalves; Marjan Ghaem-Maghami; Mona Bajaj-Elliott; Simon Clare; Bianca Neves; Gad Frankel; Gordon Dougan; Thomas T MacDonald
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

4.  Nitric oxide production by human intestinal epithelial cells and competition for arginine as potential determinants of host defense against the lumen-dwelling pathogen Giardia lamblia.

Authors:  L Eckmann; F Laurent; T D Langford; M L Hetsko; J R Smith; M F Kagnoff; F D Gillin
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  Central importance of immunoglobulin A in host defense against Giardia spp.

Authors:  T Dianne Langford; Michael P Housley; Marianne Boes; Jianzhu Chen; Martin F Kagnoff; Frances D Gillin; Lars Eckmann
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Modulation of inducible nitric oxide synthase expression by the attaching and effacing bacterial pathogen citrobacter rodentium in infected mice.

Authors:  Bruce A Vallance; Wanyin Deng; Myriam De Grado; Crystal Chan; Kevan Jacobson; B Brett Finlay
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 7.  Exploitation of host cells by enteropathogenic Escherichia coli.

Authors:  B A Vallance; B B Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

8.  B cells are required for the induction of intestinal inflammatory lesions in TCRalpha-deficient mice persistently infected with Cryptosporidium parvum.

Authors:  W R Waters; M V Palmer; M J Wannemuehler; R E Sacco; J A Harp
Journal:  J Parasitol       Date:  2000-10       Impact factor: 1.276

Review 9.  Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia.

Authors:  S A Luperchio; D B Schauer
Journal:  Microbes Infect       Date:  2001-04       Impact factor: 2.700

10.  Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection.

Authors:  Bruce A Vallance; Wanyin Deng; Leigh A Knodler; B Brett Finlay
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

View more
  101 in total

Review 1.  The role of secretory antibodies in infection immunity.

Authors:  Richard A Strugnell; Odilia L C Wijburg
Journal:  Nat Rev Microbiol       Date:  2010-08-09       Impact factor: 60.633

Review 2.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

3.  Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Citrobacter rodentium and enhances Citrobacter-induced colitis in mice.

Authors:  Chien-Chang Chen; Steve Louie; Beth McCormick; W Allan Walker; Hai Ning Shi
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 4.  Intestinal mucosal responses to microbial infection.

Authors:  Lars Eckmann; Martin F Kagnoff
Journal:  Springer Semin Immunopathol       Date:  2005-06-01

5.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

6.  Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium.

Authors:  Sarah L Lebeis; Kimberly R Powell; Didier Merlin; Melanie A Sherman; Daniel Kalman
Journal:  Infect Immun       Date:  2008-12-15       Impact factor: 3.441

7.  GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa.

Authors:  Laia Egea; Christopher S McAllister; Omar Lakhdari; Ivelina Minev; Steve Shenouda; Martin F Kagnoff
Journal:  J Immunol       Date:  2013-01-16       Impact factor: 5.422

Review 8.  Re-thinking the functions of IgA(+) plasma cells.

Authors:  Jennifer L Gommerman; Olga L Rojas; Jörg H Fritz
Journal:  Gut Microbes       Date:  2014

9.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens.

Authors:  Sara M Dann; Martina E Spehlmann; Dustin C Hammond; Mitsutoshi Iimura; Koji Hase; Lillian J Choi; Elaine Hanson; Lars Eckmann
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.